The government has confirmed that foreign workers who have a temporary stay permit (KITAS) or a permanent stay permit (KITAP) can participate in the government-funded vaccination program.
The vaccination program is being prioritized based on the risk zoning system and on the companies that have registered with the Indonesian Chamber of Commerce and Industry as a way to deal with COVID-19. The type of vaccines that will be used for this particular program is Sinopharm and CanSino.
The Sinopharm vaccines of 7 million doses are already in the country and 7.5 million further doses are expected to arrive in July 2021. The Food and Drug Administration (BPOM) has issued an emergency use authorization for the Chinese-made vaccine and has registered by PT Kimia Farma through the production of a company called Bio Institute Biological Products. Co., Ltd China.
Regarding the safety and efficacy of vaccines, a team of experts together with ITAGI and clinical experts have ensured that two doses of the Sinopharm vaccine show a good safety profile and minimal side effects.